The North America High Throughput Screening (HTS) Market is expected to witness substantial growth between 2020 and 2035, driven by innovations in drug discovery and the increasing adoption of automation technologies. In 2025, the market size is estimated at USD 10,450 Million and is projected to reach USD 24,820 Million by 2035, growing at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2035. This growth trajectory underscores the rising investment in pharmaceutical research and technological advancements across the region.
The economic impact of tariffs on "North America High Throughput Screening Market".
Market Growth Drivers
Increasing investment in pharmaceutical R&D: Leading pharmaceutical companies such as Pfizer Inc. are intensifying their efforts in research and development to accelerate drug discovery processes. This surge in R&D expenditure fuels the demand for high throughput screening platforms that facilitate rapid and cost-effective screening of chemical libraries. By leveraging HTS systems, companies are able to identify potential drug candidates more efficiently, thus reducing time-to-market and overall development costs.
Rising adoption of automation and robotics: The integration of advanced robotics and automated liquid handling systems, as exemplified by Thermo Fisher Scientific, has revolutionized the HTS market. Automation minimizes human error, enhances reproducibility, and allows for the simultaneous screening of thousands of compounds. This trend significantly boosts throughput and laboratory efficiency, making HTS an indispensable technology in modern biomedical research.
Market Trends
Expansion of AI and machine learning in screening: Companies like PerkinElmer are harnessing artificial intelligence and machine learning algorithms to analyze large datasets generated through high throughput screening. These technologies aid in predicting compound efficacy, toxicity, and pharmacological profiles, thereby optimizing hit identification rates and reducing unwanted false positives in drug discovery pipelines.
Shift towards assay miniaturization and microfluidics: Agilent Technologies has been pioneering efforts to develop miniaturized assays and microfluidic platforms that conserve reagents, lower operational costs, and increase the sensitivity of screening processes. Such innovations enable researchers to perform high-density screening with minimal sample consumption, improving efficiency and reducing waste across HTS workflows.
Market Opportunities
Personalized medicine initiatives: The growing emphasis on tailored therapies opens new avenues for HTS technology providers to collaborate with genomic and proteomic companies. Customized screening assays can identify biomarker-driven drug candidates, driving adoption among biopharmaceutical firms.
Expansion into biologics and cell-based assays: With increasing R&D in biologics, there is rising demand for HTS platforms capable of screening complex cell-based and 3D assays. This creates opportunities for companies to develop innovative solutions catering to next-generation therapeutic modalities.
North America High Throughput Screening Market Revenue (USD Million), 2020-2035
The market revenue chart demonstrates a steady upward trajectory from USD 6,250 Million in 2020 to an estimated USD 24,820 Million by 2035. The projections reflect healthy year-on-year growth, particularly from 2024 onwards, propelled by advancements in automation, expansion of pharmaceutical pipelines, and increased collaboration across academic and biopharmaceutical ecosystems. The market’s compound annual growth rate (CAGR) of 8.7% signals robust expansion potential, with investments in personalized medicine and biologics expected to accelerate adoption.
North America High Throughput Screening Market by Regional Share (%) - 2025
In 2025, the United States dominates the North America HTS market with a 74% share, driven by its well-established pharmaceutical and biotechnology sectors and significant R&D expenditure. Canada follows with a 16% share, benefiting from government initiatives and increased adoption of advanced screening technologies. Mexico holds a 5% share, with emerging interest and investments from multinational companies. Other Central American and Caribbean countries collectively account for the remaining 5% of the market, reflecting their nascent but growing participation in drug discovery and biomedical research.
Recent Developments in North America HTS Market
In April 2024, Thermo Fisher Scientific announced the launch of its next-generation, fully automated HTS platform, designed for rapid large-scale compound screening in drug discovery. The platform integrates AI analytics and high-resolution imaging, enabling researchers to increase throughput and data accuracy for more effective hit identification.
In May 2024, PerkinElmer acquired a leading microfluidics technology provider to enhance its capabilities in assay miniaturization and high-density screening. This strategic move allows PerkinElmer to offer end-to-end HTS solutions that are more sensitive, cost-effective, and suitable for cell-based and multi-omics applications.
In February 2024, Agilent Technologies partnered with a major Canadian biotech firm to advance the use of HTS in biologics development. This collaboration will jointly develop proprietary cell-based assays for monoclonal antibody and gene therapy research, leveraging HTS to accelerate the clinical pipeline and improve therapeutic discovery outcomes.
Cell-based Assays, Ultra High Throughput Screening, Lab-on-a-chip, Bioinformatics, Chemical Screening, Automation & Robotics, Drug Discovery, Toxicology, Chemical Biology, Target Identification, Lead Compound Identification, Genomics, Flow Cytometry, Mass Spectrometry, Fluorescence, Label-free Technology, Luminescence, Radioisotope, Direct Sales, Distributors/Wholesalers, E-commerce, Healthcare Institutions, Research Institutions, Contract Research Organizations, Small, Medium, Large
Press Releases